Sarepta Therapeutics (SRPT) PT Raised to $133 as RBC Capital Sees a Slim Possibility of an Early Filing

March 12, 2021 6:08 AM EST
Get Alerts SRPT Hot Sheet
Price: $71.80 -1.14%

Rating Summary:
    26 Buy, 11 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

RBC Capital analyst Brian Abrahams raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $133.00 (from $132.00) on the belief that recent addition of the 4-5yo patients to Study 103 suggests the company believes the door for early filing may still be open.

The analyst reiterated an Outperform rating, stating "We assess considerations around whether this may actually be feasible, and while we still see early filing as low likelihood, it may be in the realm of possibility and an underappreciated upside scenario we do not believe the Street is considering. The potential head start and acceleration of revenue would add +$8-15 to valuation. We believe shares are undervalued on '9001's base case opportunity, but also see add'l upside optionality on any support for earlier DMD filing".

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

RBC Capital